Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of “Hold” from Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has earned an average recommendation of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $2.00.

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. HC Wainwright downgraded Heron Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, August 11th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th.

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $0.34 on Monday. The firm has a fifty day moving average of $0.41 and a two-hundred day moving average of $0.70. The firm has a market cap of $65.29 million, a P/E ratio of -1.81 and a beta of 1.61. Heron Therapeutics has a 1-year low of $0.30 and a 1-year high of $1.57. The company has a debt-to-equity ratio of 24.35, a current ratio of 2.49 and a quick ratio of 1.51.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. The company had revenue of $37.67 million during the quarter, compared to analyst estimates of $42.19 million. As a group, research analysts anticipate that Heron Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Heron Therapeutics

Institutional investors have recently modified their holdings of the business. B. Riley Wealth Advisors Inc. acquired a new stake in Heron Therapeutics during the second quarter worth about $26,000. Advisory Services Network LLC boosted its stake in Heron Therapeutics by 2,383.4% in the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 18,114 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Heron Therapeutics during the second quarter valued at approximately $43,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $34,000. Finally, Voleon Capital Management LP bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $34,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.